Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 1, 2009, Pages 26-32

  Wang, Kebing ^a   Gao, Xin ^a   Pang, Jun ^a   Liu, Xiaopeng ^a   Cai, Yubin ^a   Zhang, Yan ^a   Zhou, Jianhua ^a   Zhan, Hailun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adenovirus; Cytokine induced killer cell; Dendritic cell; Immunotherapy; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

CYTOKINE; GAMMA INTERFERON; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOVIRIDAE; ANTIGENS, SURFACE; CELL CULTURE TECHNIQUES; CELL MEMBRANE; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; EPITOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; LYMPHOCYTES; MALE; MODELS, BIOLOGICAL; PLASMIDS;

EID: 57849144219     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.09.003     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
3. Israeli R.S., Powell C.T., Corr J.G., et al. Expression of the prostate specific membrane antigen. Cancer Res 50 (1994) 1807-1811
4. Wright G.L., Grob B.M., Haley C., et al. Up-regulation of prostate specific membrane antigen after androgen-deprivation therapy. Urology 48 (1996) 326-334
5. Lodge P.A., Jones L.A., Bader R.A., et al. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res 60 (2000) 829-833
6. Schuler G., and Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186 (1997) 1183-1187
7. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
8. Marten A., Schottker B., Ziske C., et al. Increase of the immuno-stimulatory effect of dendritic cells by pulsing with CA 19-9 protein. J Immunother 23 (2000) 464-472
9. Banchereau J., Palucka A.K., Dhodapkar M., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
10. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991) 139-149
11. Zhang S., Wang Q., Li W.F., et al. Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates. Leuk Res 28 (2004) 1085-1088
12. Marten A., Renoth S., von Lilienfeld-Toal M., et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after cocultured with idiotype-pulsed dendritic cells. Haematologica 86 (2001) 1029-1037
13. Wongkajornsilp A., Sangsuriyong S., Hongeng S., et al. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res 23 (2005) 1460-1466
14. Gonzalez-Carmona M.A., Marten A., Hoffmann P., et al. Patient-derived dendritic cells transduced with an α-fetoprotein-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26 (2006) 369-379
15. He T.C., Zhou S., Da Costa L.T., et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 (1998) 2509-2514
16. Fallaux F.J., Kranenbug O., Cramer S.J., et al. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7 (1996) 215-222
17. Graham F.L., and Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 3 (1995) 207-220
18. Ghosh A., Wang X., Klein E., et al. Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness. Cancer res 65 (2005) 727-731
19. Sweat S.D., Pacelli A., Murphy G.P., et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52 (1998) 637-640
20. Pinto J.T., Suffoletto B.P., Berzin T.M., et al. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2 (1996) 1445-1451
21. Kraaij R., van Rijswijk A.L., Oomen M.H., et al. Prostate specific membrane antigen is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate 62 (2005) 253-259
22. Butterfield L.H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127 (2004) S232-S241
23. Tjoa B.A., Simmons S.J., Bowes V.A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36 (1998) 39-44
24. Aalamian M., Pirtskhalaishvili G., Nunez A., et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 46 (2001) 68-75
25. Verneris M.R., Baker J., Edinger M., et al. Studies of ex vivo activated and expanded CD8+NK-T cells in humans and mice. J Clin Immunol 22 (2002) 131-136
26. Wood G.W., Holladay F.P., Turner T., et al. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48 (2000) 113-120
27. Zhong L., Granelli-Piperno A., Choi Y., et al. Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29 (1999) 964-972
28. Friedlander P.L., Delaune C.L., Abadie J.M., et al. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 29 (2003) 321-330
29. Jenne L., Schuler G., and Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22 (2001) 102-107
30. Kornacker M., Moldenhauer G., Herbst M., et al. Cytokine-induced killer cells against autologous CLL: Direct cytotoxic effects and induction of immune accessory molecules by interferon-γ. Int J Cancer 119 (2006) 1377-1382